Trypanosomiasis is an indication for drug development with over 100 pipeline drugs currently active. According to GlobalData, preregistered drugs for Trypanosomiasis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Trypanosomiasis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trypanosomiasis overview
Trypanosomiasis, also known as sleeping sickness in humans and nagana in animals, is a parasitic disease caused by protozoan parasites of the genus Trypanosoma. There are two main forms of the disease, each caused by different species of Trypanosoma. African trypanosomiasis (sleeping sickness) is transmitted by tsetse flies and is predominantly found in sub-Saharan Africa. It is caused by two subspecies of the parasite: Trypanosoma brucei gambiense causes the chronic form of sleeping sickness, responsible for over 90% of reported cases, which progresses slowly and can last for years without symptoms; Trypanosoma brucei rhodesiense causes the acute form, where symptoms appear within weeks to months and can lead to severe complications if untreated. American Trypanosomiasis (Chagas disease), endemic in Central and South America, is caused by the parasite Trypanosoma cruzi. Chagas disease is primarily transmitted by triatomine insects (also known as “kissing bugs”) that feed on blood. The parasites can also be transmitted through blood transfusions, organ transplants, or from mother to child during pregnancy.
For a complete picture of PTSR and LoA scores for drugs in Trypanosomiasis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
